Macbee Planet (7095) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
24 Jul, 2025Executive summary
Net sales rose 30% year-over-year to ¥24.85 billion for 1H FY04/2025, with operating profit up 23% to ¥2.47 billion, driven by medical, investment, insurance, and LTV Marketing segments.
Progressed more than half of full-year forecast, with profit attributable to owners of parent up 1.2% to ¥1.37 billion.
Transitioned to the TSE Prime Market and released a new mid-term business plan.
Announced share buyback and regular dividend, reflecting confidence in future performance.
LTV Marketing segment growth supported by new client acquisition and proprietary technology.
Financial highlights
Net sales for Q2 FY04/2025 were ¥13.29 billion, up 33.6% year-over-year.
Gross profit for Q2 was ¥2.29 billion, up 24.7% year-over-year, with a gross margin of 17.2%.
Operating profit for Q2 was ¥1.29 billion, up 28.9% year-over-year, with an operating margin of 9.7%.
EBITDA for 1H FY04/2025 reached ¥2.76 billion, up 23% year-over-year.
Ordinary profit reached ¥2.44 billion, up 22.8% year-over-year; EPS was 94.84 yen.
Outlook and guidance
Targeting ¥70 billion in sales and ¥7.5 billion in operating profit by FY04/2027, representing 78% and 104% growth from FY04/2024, respectively.
Full-year net sales forecast is ¥48 billion (up 21.8% year-over-year), with operating profit projected at ¥4.5–5.0 billion.
Annual dividend forecast for FY04/2025 is ¥36.00 per share, with an interim dividend of ¥18.00 declared.
Plans to continue large-scale advertising investments, with Q3 and Q4 ad spend projected at ¥150–200 million each.
No changes to previously announced earnings forecasts.
Latest events from Macbee Planet
- Revenue and profit fell sharply year-over-year, but full-year guidance is maintained.7095
Q3 202613 Mar 2026 - Operating profit and margin fell as revenue growth slowed, leading to a downward forecast revision.7095
Q2 202611 Dec 2025 - Q1 revenue up 11% year-over-year, but profit fell sharply on higher ad costs; recovery forecast.7095
Q1 202611 Sep 2025 - Sales and profits more than doubled, with strong outlook and a 4-for-1 stock split ahead.7095
Q4 202424 Jul 2025 - Record sales and profit growth, led by medical and LTV Marketing, with a major share buyback.7095
Q1 202524 Jul 2025 - Net sales and profits rose sharply, with upgraded guidance and strong LTV Marketing growth.7095
Q3 202524 Jul 2025 - Record sales and profit growth, with strong FY2026 outlook and expanded shareholder returns.7095
Q4 202524 Jul 2025